The global CRO where clinical trials run on time

Finding a CRO to deliver your pivotal Phase 2 & 3 clinical trials on time and on budget isn’t easy. Choose the CRO you can trust.

Therapeutic areas

Inflammatory Bowel Diseases (IBD)

Crohns’ Disease, Ulcerative Colitis and other IBDs.

Oncology

Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer and other Oncology indications.

Hematology

Multiple Myeloma, Lymphomas, Leukemias and other oncohematological indications.

Infectious Diseases

Antimicrobial and Antifungal infections and other ID.

Multiple Sclerosis

Multiple Sclerosis, Spasticity and other neurological indications.

Rare Diseases

Hemophilia A & B, Von Willebrand Disease, Thrombocytopenia, Polycythemia Vera, Paroxysmal Nocturnal Hemoglobinuria (PNH).

PSI On Point

The PSI Advantage

In 2021, PSI CRO has again received CRO Leadership Awards in five categories, including Compatibility, Expertise, Quality, Reliability, and Capabilities across two respondent groups (Overall and Small Pharma). In the Expertise category, PSI CRO is recognized as a Champion in the Leadership Awards. The CRO Leadership Awards are presented by Life Sciences Leader based on research conducted by ISR reports. The awards recognize CROs that are voted by sponsors to meet or exceed expectations.

Your last patient in is our first priority

PSI has been exceedingly professional and is respected by our site as a great collaborator.

Anthony W. Tolcher, MD, FRCP, FACP

Delivered 24 phase II and III IBD studies